Cystic fibrosis gene modifier SLC26A9 modulates airway response to CFTR-directed therapeutics.

ABSTRACT: Cystic fibrosis is realizing the promise of personalized medicine. Recent advances in drug development that target the causal CFTR directly result in lung function improvement, but variability in response is demanding better prediction of outcomes to improve management decisions. The genetic modifier SLC26A9 contributes to disease severity in the CF pancreas and intestine at birth and here we assess its relationship with disease severity and therapeutic response in the airways. SLC26A9 association with lung disease was assessed in individuals from the Canadian and French CF Gene Modifier consortia with CFTR-gating mutations and in those homozygous for the common Phe508del mutation. Variability in response to a CFTR-directed therapy attributed to SLC26A9 genotype was assessed in Canadian pa

SUBMITTER: Strug LJ 

PROVIDER: S-EPMC5886039 | biostudies-literature | 2016 Oct

REPOSITORIES: biostudies-literature